Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016
Published Oct 26, 2016
63 pages — Published Oct 26, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016, provides in depth analysis on Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1)
- The report reviews Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Superoxide Dismutase [Cu-Z

  
Source:
Document ID
GMDHC0608TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Overview71
Therapeutics Development83
  Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Stage of Development81
  Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Therapy Area91
  Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Indication101
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Companies132
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Products under Development by Universities/Institutes152
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Therapeutics Assessment177
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action182
  Assessment by Route of Administration202
  Assessment by Molecule Type222
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Companies Involved in Therapeutics Development246
  Ionis Pharmaceuticals, Inc.241
  Neurimmune Holding AG251
  ProMIS Neurosciences Inc.261
  Thera Neuropharma Inc271
  Voyager Therapeutics, Inc.281
  Wilson Therapeutics AB291
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Drug Profiles3019
  ISIS-SOD1Rx Drug Profile302
  Monoclonal Antibodies to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis Drug Profile322
  Monoclonal Antibody 1 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile341
  Monoclonal Antibody 2 to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile351
  Monoclonal Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis Drug Profile361
  NI-204 Drug Profile371
  RNAi Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis Drug Profile381
  Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson's Disease Drug Profile391
  Small Molecules to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis Drug Profile401
  TDI-186 Drug Profile411
  tetrathiomolybdate Drug Profile421
  THN-1 Drug Profile432
  VYSOD-101 Drug Profile451
  WTX-101 Drug Profile463
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Dormant Projects491
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) Featured News &Press Releases5012
  Jun 23, 2016: Wilson Therapeutics Presents Preliminary Clinical Data on Decuprate at the 20th International Congress of Parkinson's Disease and Movement Disorders501
  May 30, 2016: Wilson Therapeutics Presents Encouraging Clinical Data On Decuprate At The Congress Of The European Academy Of Neurology501
  May 18, 2016: Wilson Therapeutics Announces That the Ongoing Phase II Study Has Been Fully Enrolled511
  Apr 29, 2016: Voyager Therapeutics Highlights Program in ALS Disease521
  Apr 14, 2016: Wilson Therapeutics presents data on Decuprate (WTX101) from ongoing Phase 2 study at The International Liver Congress 2016521
  Dec 11, 2015: Isis Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of ISIS-SOD1 Rx in Patients With ALS531
  Apr 16, 2015: Wilson Therapeutics Announces Presentation Of WTX101-201 Phase 2 Study At The EASL 50th International Liver Congress 2015541
  Nov 17, 2014: Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients541
  Jan 13, 2014: Wilson Therapeutics Announces Successful Filing of U.S. IND to Advance WTX101 Development Program for Wilson Disease551
  Apr 03, 2013: MGH And Washington University Researchers Announce Isis Pharma's SOD1 Antisense Drug Demonstrates Safety In Phase I ALS Trial552
  Feb 13, 2013: Copper Depletion Therapy May Prevent Risk Of Triple-Negative Breast Cancer, Study Finds572
  Apr 28, 2011: RXi Pharmaceuticals and the University of Massachusetts Medical School Announce Massachusetts Life Sciences Center Cooperative Research Grant for RNAi Therapeutics for ALS591
  Mar 08, 2010: ISIS Initiates Phase I Clinical Trial Of ISIS-SOD1Rx In Patients With Amyotrophic Lateral Sclerosis601
  Dec 13, 2007: Isis Pharmaceuticals Announces ISIS 333611 Granted Orphan Drug Status For Treatment Of ALS601
  May 24, 2004: Attenuon Announces Launch Of ATN-224 Phase I Trial In Patients With Solid Tumors611
Appendix622
  Methodology621
  Coverage621
  Secondary Research621
  Primary Research621
  Expert Panel Validation621
  Contact Us621
  Disclaimer631

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Superoxide-Dismutase-Cu-Zn-Superoxide-Dismutase-1-or-Epididymis-Secretory-Protein-Li-44-or-SOD1-or-EC-1-15-1-1-Pipeline-Review-H2-2016-2088-16889>
  
APA:
Global Markets Direct - Market Research. (2016). Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Superoxide-Dismutase-Cu-Zn-Superoxide-Dismutase-1-or-Epididymis-Secretory-Protein-Li-44-or-SOD1-or-EC-1-15-1-1-Pipeline-Review-H2-2016-2088-16889>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.